We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Simple Bile Acid Blood Test Predicts Stillbirth Risk

By LabMedica International staff writers
Posted on 25 Feb 2019
Intrahepatic cholestasis of pregnancy (ICP) is caused by a build-up of bile acids in the blood, and symptoms include pruritus. More...
ICP is a liver disorder affecting approximately 5,300 pregnancies annually in the UK, more than 14 every day.

ICP is diagnosed in women with gestational pruritus and increased serum bile acids, and can be complicated by preterm labor, fetal asphyxia, meconium-stained amniotic fluid, and stillbirth. It was previously thought that small increases in bile acid concentration are associated with higher risks of stillbirth. Pregnant women showing symptoms of ICP, therefore, are often offered early induction of labor at around 37 weeks in order to prevent stillbirth.

A large team of international scientists collaborating with Kings College London (London, UK) analyzed more than 170,000 pregnancies from 40 international studies to understand the link between ICP, bile acid levels and stillbirth. The results of the study show that for the majority of women with ICP, who have bile acid concentration below 100 μmol/, the risk of stillbirth is not significantly greater than that of pregnant women without ICP. This means they need no further treatment other than regular bile acid blood tests for the remainder of their pregnancy.

The scientists reported that stillbirth occurred in 45/4,936 (0.83%) of intrahepatic cholestasis of pregnancy cases and 519/163,947 (0.32%) of control pregnancies (odds ratio [OR] 1.46). In singleton pregnancies, stillbirth was associated with maximum total bile acid concentration (area under the receiver operating characteristic curve [ROC AUC] 0.83), but not alanine aminotransferase (ROC AUC 0·46). For singleton pregnancies, the prevalence of stillbirth was 3/2,310 (0.13%) of intrahepatic cholestasis of pregnancy cases in women with serum total bile acids of less than 40 μmol/L versus 4/1,412 (0.28%) of cases with total bile acids of 40–99 μmol/L (hazard ratio [HR] 2.35), and versus 18/524 (3.44%) of cases for bile acids of 100 μmol/L or more (HR 30.5).

Caroline Ovadia, BCh, a Clinical Lecturer and first author of the study, said, “This marks a real step forward in the diagnosis and management of liver disorders during pregnancy. Being able to measure the risks to women and their babies by simple tests allows doctors to concentrate treatment on those who really need it. It also means that women will not have to be offered preterm birth unnecessarily which comes with associated risks to their babies including admission to neonatal units, breathing problems and jaundice.” The study was published on February 14, 2019, in the journal The Lancet.

Related Links:
Kings College London


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.